Key facts
- Notable investors include HaiBang Ventures, CUFE Rising Capital, Bohai Chuangfu Securities Investment, Jintan Capital, Kaitai Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Yunying Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Yunying Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yunying Medicine
Developer of technologies and reagents for molecular diagnostic testing services designed to provide genetic profiling for tumor detection and monitoring. The company offers multi modal high throughput sequencing panels, minimal residual disease monitoring assays, targeted and methylation based testing strategies, and integrated liquid biopsy capabilities, enabling oncologists, clinical laboratories, and hospital based testing facilities to maintain continuous patient monitoring throughout the cancer care continuum.
- Sector
- Healthcare
- HQ
- Jiaxing, China
- Founded
- 2015
- Website
- yymedicine.com/
- Ownership
- Privately Held (backing)
Yunying Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yunying Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yunying Medicine in its N-PORT filings yet. We sweep new filings monthly.